denbufylline has been researched along with Ischemic Attack, Transient in 1 studies
denbufylline: structure given in first source
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willette, RN | 1 |
| Shiloh, AO | 1 |
| Sauermelch, CF | 1 |
| Sulpizio, A | 1 |
| Michell, MP | 1 |
| Cieslinski, LB | 1 |
| Torphy, TJ | 1 |
| Ohlstein, EH | 1 |
1 other study available for denbufylline and Ischemic Attack, Transient
| Article | Year |
|---|---|
Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-AMP Phosphodiestera | 1997 |